EarningsQ2 2026 Earnings Report
MX:AMN.STR Q2 2026 EPS Results
Actual EPS$13.06
Consensus EPS$3.21
Beat/MissBeat by +$9.85
One Year Ago EPS$5.09
MX:AMN.STR Q2 2026 Revenue Results
Actual Revenue$11.42B
Expected Revenue$10.66B
Beat/MissBeat by +$760.57M
YoY Revenue Growth+2.29%
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeAfter Close
Conference CallThursday, August 6, 2026
MX:AMN.STR Upcoming Earnings
AMN Healthcare Services's next earnings date is estimated for October 29, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:AMN.STR Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented multiple strong operational and financial highlights — revenue beat, sizable adjusted EBITDA and EPS improvement, robust cash balance, low leverage, strong Nurse & Allied performance, accelerated travel and allied volumes, and meaningful product adoption and search momentum. Several targeted acquisitions and improved operational automation/AI capabilities support longer-term growth. Offsetting these positives are notable near-term headwinds: Technology & Workforce Solutions and language services revenue declines and pricing pressure, a weaker locum/physician segment, and the fact that the Q2 outperformance was partly driven by nonrecurring items that will not repeat in Q3. Management provided conservative Q3 guidance reflecting normalization. Overall, the company appears well-positioned financially and operationally, with manageable short-term challenges and a constructive outlook into 2027.Company Guidance
Consolidated Revenue Beat
Second quarter consolidated revenue of $673 million, which was 6% above the high end of guidance and grew 2% year-over-year.
Adjusted EBITDA and EPS Surge
Adjusted EBITDA of $73 million (10.9% of revenue) increased 26% year-over-year; adjusted EPS was $0.77 versus $0.30 in the prior-year quarter.
Strong Cash Position and Leverage
Ended the quarter with $362 million in cash and equivalents (well above expectation) and total debt of $750 million with a leverage ratio of 1.5x per credit agreement.
Nurse & Allied Segment Outperformance
Nurse & Allied revenue of $422 million grew 11% year-over-year and was 12% ahead of consensus; segment gross margin 28.4% and segment operating margin 13.8%.
Travel Nurse and Allied Volume Growth
Travel nurse volume grew 6% year-over-year and allied volume grew 7% year-over-year — the highest growth rates for these businesses in four years; orders turned positive in May and accelerated in June.
International Nurse Momentum
International nurse revenue grew 23% year-over-year in Q2, benefiting from visa date progress (though subject to visa interview capacity).
Search & Leadership Momentum
Physician search showed strong growth: physician search new searches +40% year-over-year (37% sequentially), executive search +30% year-over-year, leadership search volume +60%.
Product & Platform Adoption
Passport clinician network surpassed 400,000 users, up 33% year-over-year; monthly active users increased by more than 50% year-over-year, enhancing sourcing scale.
Targeted, Strategic Acquisitions
Made two small strategic acquisitions (Jaide Health and ESSENTIAL Brand Leadership) to extend language and leadership capabilities; total spend ~$3 million and early traction reported.
Improved Operational Efficiency
Adjusted SG&A was $135 million, down 4% year-over-year (ex certain items); DSO 52 days (54 adjusted) and strong working capital impacts supported cash outperformance.
MX:AMN.STR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed